PET radiotracers: crossing the blood-brain barrier and surviving metabolism

Trends in Pharmacological Sciences

Volumn 30, Issue 8, 2009, Pages 431-440

  Pike, Victor W ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (2 AZETIDINYLMETHOXY)PYRIDINE; 5 (7 BENZOFURANYL) 8 CHLORO 2,3,4,5 TETRAHYDRO 7 HYDROXY 3 METHYL 1H 3 BENZAZEPINE; A 35380; BENZODIAZEPINE RECEPTOR; BRAIN RECEPTOR; CARBON 11; CARBON DIOXIDE; CARRIER PROTEIN; CHOLINERGIC RECEPTOR; COCAINE; DIPRENORPHINE; DOPAMINE 2 RECEPTOR; FLUMAZENIL; FLUORINE 18; FORMALDEHYDE; GLYCOPROTEIN P; LOPERAMIDE; METABOTROPIC RECEPTOR 5; MULTIDRUG RESISTANCE PROTEIN; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; OPIATE RECEPTOR; PHOSPHODIESTERASE IV; RACLOPRIDE; ROLIPRAM; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; TRACER; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; VOLINANSERIN;

ACCURACY; BLOOD BRAIN BARRIER; DENSITY; DRUG DESIGN; DRUG METABOLISM; DRUG PENETRATION; DRUG RESEARCH; DRUG STRUCTURE; HUMAN; LIPOPHILICITY; MEDICAL RESEARCH; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; DRUG DELIVERY SYSTEMS; HUMANS; MEMBRANE TRANSPORT PROTEINS; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; POSITRON-EMISSION TOMOGRAPHY; RADIOACTIVE TRACERS; RADIOPHARMACEUTICALS;

EID: 67849083569     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2009.05.005     Document Type: Review

References (80)

1. Jacobs A.H., et al. PET-based molecular imaging in neuroscience. Eur. J. Nucl. Med. Mol. Imaging 30 (2003) 1051-1065
2. Lee C.-M., and Farde L. Using positron emission tomography to facilitate drug development. Trends Pharmacol. Sci. 27 (2006) 310-316
3. Fowler J.S., and Ido T. In: Welch M.J., and Redvanly C.S. (Eds). Handbook of Radiopharmaceuticals, Radiochemistry and Applications (2003), Wiley 307-321
4. Pike V.W. Positron-emitting radioligands for studies in vivo - probes for human psychopharmacology. J. Psychopharmacol. 7 (1993) 139-158
5. Laruelle M., et al. Relationships between radiotracer properties and image quality in molecular imaging of the brain with positron emission tomography. Mol. Imaging Biol. 5 (2003) 363-375
6. Lee G., and Bendayan R. Functional expression and localization of P-glycoprotein in the central nervous system: relevance to the pathogenesis and treatment of neurological disorders. Pharm. Res. 21 (2004) 1313-1330
7. Dallas S., et al. Multidrug resistance-associated proteins: expression and function in the central nervous system. Pharmacol. Rev. 58 (2006) 140-161
8. Innis R.B., et al. Concensus nomenclature for in vivo imaging of reversibly binding radioligands. J. Cereb. Blood Flow Metab. 27 (2007) 1533-1539
9. Raub T.J. P-glycoprotein recognition of substrates and circumvention through rational drug design. Mol. Pharm. 3 (2006) 3-25
10. Fischer H., et al. Blood-brain barrier permeation: molecular parameters governing passive diffusion. J. Membr. Biol. 165 (1998) 201-211
11. Gerebtzoff G., and Seelig A. In silico prediction of blood-brain barrier permeation using the calculated molecular cross-sectional area as main parameter. J. Chem. Inf. Model. 46 (2006) 2638-2650
12. Seelig A. The role of size and charge for blood-brain barrier permeation of drugs and fatty acids. J. Mol. Neurosci. 33 (2007) 32-41
13. Waterhouse R.N. Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents. Mol. Imaging Biol. 5 (2003) 376-389
14. 1) receptor ligands as candidates for in vivo imaging. J. Med. Chem. 51 (2008) 5833-5842
15. 1 receptors in nonhuman primate brain. Neuropsychopharmacology 33 (2008) 259-269
16. 11C]MePPEP, in rodents and humans. Neuroimage 41 Suppl. 2 (2008) T197
17. Elsinga P.H., et al. PET studies on P-glycoprotein function in the blood-brain barrier: how it affects uptake and binding of drugs within the CNS. Curr. Pharm. Des. 10 (2004) 1493-1503
18. Ishiwata K., et al. In vivo evaluation of P-glycoprotein modulation of 8 PET radioligands used clinically. J. Nucl. Med. 48 (2007) 81-87
19. Syvänen S., et al. Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport. Drug Metab. Dispos. 37 (2009) 635-643
20. Elsinga P.H., et al. Positron emission tomography studies on binding of central nervous system drugs and P-glycoprotein function in the rodent brain. Mol. Imaging Biol. 7 (2005) 37-44
21. 11C](R)-(-)-RWAY. Synapse 61 (2007) 96-105
22. 18F]MPPF in rats. Eur. J. Pharmacol. 407 (2000) 273-280
23. 18F]MPPF uptake in rat brain and peripheral tissues: microPET and ex vivo studies. Eur. J. Nucl. Med. Mol. Imaging 35 (2008) 2256-2266
24. 1A receptors in the primate brain. Psychopharmacology (Berl.) 133 (1997) 196-202
25. 11C](-)-RWAY. Synapse 60 (2006) 510-520
26. 1A receptors in humans. Synapse 25 (1997) 147-154
27. 11C]WAY-100635. Eur. J. Pharmacol. 301 (1996) R5-R7
28. 11C](R)-(-)-RWAY: radiometabolite(s) likely confound brain measurements. Synapse 61 (2007) 469-477
29. 18F]MPPF. J. Nucl. Med. 41 (2000) 1830-1835
30. Doze P., et al. Enhanced cerebral uptake of receptor ligands by modulation of P-glycoprotein function in the blood-brain barrier. Synapse 36 (2000) 66-74
31. 11C]N-desmethyl-loperamide as a new and improved PET radiotracer for imaging P-gp function. J. Med. Chem. 51 (2008) 6034-6043
32. Summerfield S.G., et al. Improving the in vitro prediction of in vivo central nervous system penetration: integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain. J. Pharmacol. Exp. Ther. 316 (2006) 1282-1290
33. Summerfield S.G., et al. Toward an improved prediction of human in vivo brain penetration. Xenobiotica 38 (2008) 1518-1535
34. Willemsen A.T.M., and van den Hoff J. Fundamentals of quantitative PET data analysis. Curr. Pharm. Des. 8 (2002) 1513-1526
35. 11C]verapamil transfer at the human blood-brain barrier for evaluation of P-glycoprotein function. J. Nucl. Med. 47 (2006) 1531-1537
36. 11C]verapamil as PET tracer of P-glycoprotein function at the blood-brain barrier: kinetics and metabolism in the rat. Nucl. Med. Biol. 32 (2005) 87-93
37. Pauli-Magnus C., et al. Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. J. Pharmacol. Exp. Ther. 293 (2000) 376-382
38. 11C-Loperamide and its N-desmethyl radiometabolite are avid substrates for brain P-glycoprotein efflux. J. Nucl. Med. 49 (2008) 649-656
39. 11C-N-desmethyl-loperamide. J. Nucl. Med. 50 (2009) 108-115
40. 11C-N-desmethyl-loperamide, a positron emission tomography radioligand to measure the function of P-glycoprotein. J. Nucl. Med. 50 (2009) 807-813
41. Okamura T., et al. Noninvasive and quantitative assessment of the function of multidrug resistance-associated protein 1 in the living brain. J. Cerebr. Blood Flow Metab. 29 (2009) 504-511
42. 18F]FECNT: a polar radioactive metabolite confounds brain activity measurements. J. Nucl. Med. 47 (2006) 520-527
43. 11C]PE2I. Eur. J. Nucl. Med. Mol. Imaging 34 (2007) 667-678
44. 11C]PE2I: quantitative modeling and test-retest reproducibility. J. Cereb. Blood Flow Metab. 28 (2008) 1059-1069
45. 1A receptors. Eur. J. Nucl. Med. Mol. Imaging 34 (2007) 1670-1682
46. 18F-labeled ligand for imaging brain peripheral benzodiazepine receptors with PET. J. Med. Chem. 52 (2009) 688-699
47. Fujimura, Y. et al. Quantification of peripheral benzodiazepine receptors in human brain with positron emission tomography and 18F-PBR06. J. Nucl. Med. DOI: 10.2967/jnumed.108.060186 (http://jnm.snmjournals.org)
48. 18F]SP203) as a radioligand for imaging brain metabotropic glutamate subtype-5 receptors with PET. J. Med. Chem. 50 (2007) 3256-3266
49. Brown A.K., et al. Metabotropic glutamate subtype-5 (mGluR5) receptors quantified in human brain with a novel radioligand for positron emission tomography. J. Nucl. Med. 49 (2008) 2042-2048
50. 18F]SP203), a radioligand for imaging brain mGluR5 in vivo, is defluorinated by glutathionylation in rat brain. J. Pharmacol. Exp. Ther. 327 (2008) 727-735
51. 11C]cocaine metabolites contribute to PET images of the baboon brain. J. Neurochem. 62 (1994) 1154-1162
52. 11C]flumazenil. Neuroimage 45 (2009) 891-902
53. 11C]WAY-100635. Med. Chem. Res. 5 (1995) 208-227
54. 11C]WAY-100635, in monkey and human plasma by HPLC - comparison of the behaviour of an identified radioactive metabolite with parent radioligand in monkey using PET. Nucl. Med. Biol. 23 (1996) 627-634
55. 11C]WAY-100635 - explanation of high signal in PET and an aid to biomathematical modelling. Nucl. Med. Biol. 25 (1998) 215-223
56. 2 - reduction in metabolic trapping rate in brain. Nucl. Med. Biol. 13 (1986) 79-80
57. 11C]L-deprenyl in living baboon brain. J. Neurochem. 51 (1988) 1524-1534
58. Schou M., et al. PET evaluation of novel radiofluorinated reboxetine analogs as norepeienphrine transporter probes in the monkey brain. Synapse 53 (2004) 57-67
59. 18F]FEPPA for PET imaging of peripheral benzodiazepine receptors. Nucl. Med. Biol. 35 (2008) 305-314
60. 11C-labeled aryloxyanilide ligands for imaging brain peripheral benzodiazepine receptors in vivo. J. Med. Chem. 51 (2008) 17-30
61. 18F]FCWAY and improvement by successful inhibition of defluorination with miconazole. J. Nucl. Med. 47 (2006) 1-9
62. 1A receptors in human brain. J. Nucl. Med. 48 (2007) 1154-1161
63. 18F]CPFPX by CYP1A2: implications of bolus/infusion studies. Nucl. Med. Biol. 33 (2006) 891-898
64. 18F]CPFPX) in rodents and humans. Drug Metab. Dispos. 34 (2006) 570-576
65. 18F]Fluoro-A-85380, a new PET tracer for the nicotonic acetylcholine receptor: studies in the human brain and in vivo demonstration of specific binding in white matter. Synapse 53 (2004) 184-189
66. 11C]β-CFT in early Parkinson's disease. Synapse 21 (1995) 97-103
67. 18F]SPA-RQ in human subjects: assessment of reference tissue models and their test-retest reproducibility. Synapse 61 (2007) 242-251
68. 18F-fallypride in normal volunteers: blood analysis, distribution, test-retest studies, and preliminary assessment of sensitivity to aging effects on dopamine D-2/D-3 receptors. Synapse 46 (2002) 170-188
69. 11C]diprenorphine cerebral kinetics in man acquired by PET using presaturation, pulse-chase and tracer only protocols. J. Neurosci. Methods 51 (1994) 123-134
70. 11C]rolipram and positron emission tomography. Eur. J. Nucl. Med. 29 (2002) 1680-1683
71. Farde L., et al. Subsituted benzamides as ligands for visualization of dopamine receptor binding in the human brain by positron emission tomography. Proc. Natl. Acad. Sci. U. S. A. 82 (1985) 3863-3867
72. 11C]WAY-100635 in the human brain. J. Nucl. Med. 43 (2002) 292-303
73. 11C]MDL 100,907. J. Cereb. Blood Flow Metab 27 (2007) 161-172
74. Fujita M., et al. Kinetic analysis in healthy humans of a novel positron emission tomography radioligand to image the peripheral benzodiazepine receptor, a potential marker for inflammation. Neuroimage 40 (2008) 43-52
75. Klunk W.E. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann. Neurol. 55 (2004) 306-319
76. 11C]-DASB binding to the human serotonin transporter: modeling strategies. J. Cereb. Blood Flow Metab. 21 (2001) 1342-1353
77. 11C]PK11195 brain studies. J. Cereb. Blood Flow Metab. 25 (2005) 842-851
78. 1-dopamine receptors. J. Nucl. Med. 39 (1998) 2061-2068
79. 11C]WAY-100635. Neuroimage 8 (1998) 426-440
80. 11C]WAY-100635 binding to central 5-hydroxytryptamine 1A receptors in man. J. Nucl. Med. 39 (1998) 1965-1971